Business
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1). The study, entitled "Nanotherapy Targeting miR-10b Improv
About this update from Transcode Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma models","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Study supports future clinical development of TTX-MC138 for patients with glioblastoma","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":304,"olType":false},{"type":"text","content":"BOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1). The study, entitled "Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models," resulted from a collaboration between TransCode and Michigan State University. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean for Research Development at the College of Human Medicine at Michigan State University and scientific co-founder of TransCode.","length":909,"tagName":"p"},{"type":"image","alt":"TransCode Therapeutics, Inc. logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"TransCode Therapeutics, Inc. logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/b0561ee1cbd7c692705f747a1a2c23a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xcCTGMwRUnjgvJmiy6SfWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b0561ee1cbd7c692705f747a1a2c23a8","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2843185/TransCode_Therapeutics_Inc.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Glioblastoma is the most aggressive primary brain cancer, with median survi...